Literature DB >> 26016690

Bacterial Renalase: Structure and Kinetics of an Enzyme with 2- and 6-Dihydro-β-NAD(P) Oxidase Activity from Pseudomonas phaseolicola.

Matthew R Hoag1, Joseph Roman1, Brett A Beaupre1, Nicholas R Silvaggi1, Graham R Moran1.   

Abstract

Despite a lack of convincing in vitro evidence and a number of sound refutations, it is widely accepted that renalase is an enzyme unique to animals that catalyzes the oxidative degradation of catecholamines in blood in order to lower vascular tone. Very recently, we identified isomers of β-NAD(P)H as substrates for renalase (Beaupre, B. A. et al. (2015) Biochemistry, 54, 795-806). These molecules carry the hydride equivalent on the 2 or 6 position of the nicotinamide base and presumably arise in nonspecific redox reactions of nicotinamide dinucleotides. Renalase serves to rapidly oxidize these isomers to form β-NAD(P)⁺ and then pass the electrons to dioxygen, forming H₂O₂. We have also shown that these substrate molecules are highly inhibitory to dehydrogenase enzymes and thus have proposed an intracellular metabolic role for this enzyme. Here, we identify a renalase from an organism without a circulatory system. This bacterial form of renalase has the same substrate specificity profile as that of human renalase but, in terms of binding constant (K(d)), shows a marked preference for substrates derived from β-NAD⁺. 2-dihydroNAD(P) substrates reduce the enzyme with rate constants (k(red)) that greatly exceed those for 6-dihydroNAD(P) substrates. Taken together, k(red)/K(d) values indicate a minimum 20-fold preference for 2DHNAD. We also offer the first structures of a renalase in complex with catalytically relevant ligands β-NAD⁺ and β-NADH (the latter being an analogue of the substrate(s)). These structures show potential electrostatic repulsion interactions with the product and a unique binding orientation for the substrate nicotinamide base that is consistent with the identified activity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26016690     DOI: 10.1021/acs.biochem.5b00451

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

Review 1.  The chemistry of the vitamin B3 metabolome.

Authors:  Mikhail V Makarov; Samuel A J Trammell; Marie E Migaud
Journal:  Biochem Soc Trans       Date:  2018-12-17       Impact factor: 5.407

2.  Ligand binding phenomena that pertain to the metabolic function of renalase.

Authors:  Brett A Beaupre; Joseph V Roman; Matthew R Hoag; Kathleen M Meneely; Nicholas R Silvaggi; Audrey L Lamb; Graham R Moran
Journal:  Arch Biochem Biophys       Date:  2016-10-18       Impact factor: 4.013

3.  RENALASE: DISCOVERY, BIOLOGY, AND THERAPEUTIC APPLICATIONS.

Authors:  Gary V Desir
Journal:  Trans Am Clin Climatol Assoc       Date:  2022

4.  Bioinformatic Analysis of the Flavin-Dependent Amine Oxidase Superfamily: Adaptations for Substrate Specificity and Catalytic Diversity.

Authors:  Margarita A Tararina; Karen N Allen
Journal:  J Mol Biol       Date:  2020-03-19       Impact factor: 5.469

5.  Residues 28 to 39 of the Extracellular Loop 1 of Chicken Na+/H+ Exchanger Type I Mediate Cell Binding and Entry of Subgroup J Avian Leukosis Virus.

Authors:  Xiaolu Guan; Yao Zhang; Mengmeng Yu; Chaoqi Ren; Yanni Gao; Bingling Yun; Yongzhen Liu; Yongqiang Wang; Xiaole Qi; Changjun Liu; Hongyu Cui; Yanping Zhang; Li Gao; Kai Li; Qing Pan; Baoshan Zhang; Xiaomei Wang; Yulong Gao
Journal:  J Virol       Date:  2017-12-14       Impact factor: 5.103

6.  Chemical and Biochemical Reactivity of the Reduced Forms of Nicotinamide Riboside.

Authors:  Mikhail V Makarov; Faisal Hayat; Briley Graves; Manoj Sonavane; Edward A Salter; Andrzej Wierzbicki; Natalie R Gassman; Marie E Migaud
Journal:  ACS Chem Biol       Date:  2021-03-30       Impact factor: 5.100

7.  Improved soluble expression and use of recombinant human renalase.

Authors:  Clifford S Morrison; Elena E Paskaleva; Marvin A Rios; Thomas R Beusse; Elaina M Blair; Lucy Q Lin; James R Hu; Aidan H Gorby; David R Dodds; William B Armiger; Jonathan S Dordick; Mattheos A G Koffas
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.